Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Rumah, Kareem Rashid ^a,b,c   Linden, Jennifer ^b   Fischetti, Vincent A ^c   Vartanian, Timothy ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM PERFRINGENS INFECTION; CLOSTRIDIUM PERFRINGENS TYPE A; CLOSTRIDIUM PERFRINGENS TYPE B; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; TROPISM; WHITE MATTER;

ADULT; BACTERIAL TOXINS; BRAIN; CASE-CONTROL STUDIES; CLOSTRIDIUM PERFRINGENS; ENDOTHELIAL CELLS; ENVIRONMENT; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; PREVALENCE; PROTEIN BINDING; RETINAL VESSELS; YOUNG ADULT;

EID: 84885709166     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076359     Document Type: Article

References (75)

1. Adams RD, Kubik CS, (1952) The morbid anatomy of the demyelinative disease. The American journal of medicine 12: 510-546.
2. Barnett MH, Prineas JW, (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Annals of neurology 55: 458-468.
3. Prineas JW, Parratt JD, (2012) Oligodendrocytes and the early multiple sclerosis lesion. Annals of neurology 72: 18-31 doi: 10.1002/ana.23634.
4. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI, (1991) The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain: a journal of neurology 114 (Pt 3): 1271-1280.
5. Barnett MH, Henderson AP, Prineas JW, (2006) The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Multiple sclerosis 12: 121-132.
6. Barnett MH, Parratt JD, Cho ES, Prineas JW, (2009) Immunoglobulins and complement in postmortem multiple sclerosis tissue. Annals of neurology 65: 32-46 doi: 10.1002/ana.21524.
7. Popoff MR, Bouvet P, (2009) Clostridial toxins. Future microbiology 4: 1021-1064 doi: 10.2217/fmb.09.72.
8. Popoff MR, (2011) Epsilon toxin: a fascinating pore-forming toxin. The FEBS journal 278: 4602-4615 doi: 10.1111/j.1742-4658.2011.08145.x.
9. Souza AM, Reis JKP, Assis RA, Horta CC, Siqueira FF, et al. (2010) Molecular cloning and expression of epsilon toxin from Clostridium perfringens type D and tests of animal immunization. Genetics and molecular research: GMR 9: 266-276 doi: 10.4238/vol9-1gmr711.
10. Bokori-Brown M, Savva CG, Fernandes da Costa SP, Naylor CE, Basak AK, et al. (2011) Molecular basis of toxicity of Clostridium perfringens epsilon toxin. The FEBS journal 278: 4589-4601 doi: 10.1111/j.1742-4658.2011.08140.x.
11. Fernandez Miyakawa ME, Uzal FA, (2003) The early effects of Clostridium perfringens type D epsilon toxin in ligated intestinal loops of goats and sheep. Veterinary research communications 27: 231-241.
12. Uzal FA, (2004) Diagnosis of Clostridium perfringens intestinal infections in sheep and goats. Anaerobe 10: 135-143 doi: 10.1016/j.anaerobe.2003.08.005.
13. Uzal FA, Kelly WR, Morris WE, Bermudez J, Baison M, (2004) The pathology of peracute experimental Clostridium perfringens type D enterotoxemia in sheep. J Vet Diagn Invest 16: 403-411.
14. Uzal FA, Songer JG, (2008) Diagnosis of Clostridium perfringens intestinal infections in sheep and goats. J Vet Diagn Invest 20: 253-265.
15. Garcia JP, Adams V, Beingesser J, Hughes ML, Poon R, et al. (2013) Epsilon Toxin Is Essential for the Virulence of Clostridium perfringens Type D Infection in Sheep, Goats, and Mice. Infection and immunity 81: 2405-2414 doi: 10.1128/IAI.00238-13.
16. Fernandez Miyakawa ME, Ibarra CA, Uzal FA, (2003) In vitro effects of Clostridium perfringens type D epsilon toxin on water and ion transport in ovine and caprine intestine. Anaerobe 9: 145-149 doi: 10.1016/S1075-9964(03)00069-6.
17. Goldstein J, Morris WE, Loidl CF, Tironi-Farinati C, McClane BA, et al. (2009) Clostridium perfringens epsilon toxin increases the small intestinal permeability in mice and rats. PloS one 4: e7065 doi: 10.1371/journal.pone.0007065.
18. Li J, Sayeed S, Robertson S, Chen J, McClane BA, (2011) Sialidases affect the host cell adherence and epsilon toxin-induced cytotoxicity of Clostridium perfringens type D strain CN3718. PLoS pathogens 7: e1002429 doi: 10.1371/journal.ppat.1002429.
19. Murrell TG, O'Donoghue PJ, Ellis T, (1986) A review of the sheep-multiple sclerosis connection. Medical hypotheses 19: 27-39.
20. Gleeson-White MH, Bullen JJ, (1955) Clostridium welchii epsilon toxin in the intestinal contents of man. Lancet 268: 384-385.
21. Hatheway CL, (1990) Toxigenic clostridia. Clin Microbiol Rev 3: 66-98.
22. Balali-Mood M, Moshiri M, Etemad L, (2013) Medical aspects of bio-terrorism. Toxicon: official journal of the International Society on Toxinology 69: 131-142 doi: 10.1016/j.toxicon.2013.01.005.
23. Nagahama M, Sakurai J, (1991) Distribution of labeled Clostridium perfringens epsilon toxin in mice. Toxicon: official journal of the International Society on Toxinology 29: 211-217.
24. Nagahama M, Sakurai J, (1992) High-affinity binding of Clostridium perfringens epsilon-toxin to rat brain. Infection and immunity 60: 1237-1240.
25. Dorca-Arévalo J, Soler-Jover A, Gibert M, Popoff MR, Martín-Satué M, et al. (2008) Binding of epsilon-toxin from Clostridium perfringens in the nervous system. Veterinary microbiology 131: 14-25 doi: 10.1016/j.vetmic.2008.02.015.
26. Wioland L, Dupont JL, Bossu JL, Popoff MR, Poulain B (2013) Attack of the nervous system by Clostridium perfringens Epsilon toxin: From disease to mode of action on neural cells. Toxicon: official journal of the International Society on Toxinology, doi: 10.1016/j.toxicon.2013.04.003.
27. Petit L, Gibert M, Gillet D, Laurent-Winter C, Boquet P, et al. (1997) Clostridium perfringens epsilon-toxin acts on MDCK cells by forming a large membrane complex. Journal of bacteriology 179: 6480-6487.
28. Chassin C, Bens M, de Barry J, Courjaret R, Bossu JL, et al. (2007) Pore-forming epsilon toxin causes membrane permeabilization and rapid ATP depletion-mediated cell death in renal collecting duct cells. American journal of physiology. Renal physiology 293: F927-937 doi: 10.1152/ajprenal.00199.2007.
29. Miyata S, Minami J, Tamai E, Matsushita O, Shimamoto S, et al. (2002) Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. The Journal of biological chemistry 277: 39463-39468 doi: 10.1074/jbc.M206731200.
30. Kitadokoro K, Nishimura K, Kamitani S, Fukui-Miyazaki A, Toshima H, et al. (2011) Crystal structure of Clostridium perfringens enterotoxin displays features of beta-pore-forming toxins. The Journal of biological chemistry 286: 19549-19555 doi: 10.1074/jbc.M111.228478.
31. Robertson SL, Li J, Uzal FA, McClane BA, (2011) Evidence for a prepore stage in the action of Clostridium perfringens epsilon toxin. PloS one 6: e22053 doi: 10.1371/journal.pone.0022053.
32. Finnie JW, (1984) Ultrastructural changes in the brain of mice given Clostridium perfringens type D epsilon toxin. Journal of comparative pathology 94: 445-452.
33. Finnie JW, (1984) Histopathological changes in the brain of mice given Clostridium perfringens type D epsilon toxin. Journal of comparative pathology 94: 363-370.
34. Finnie JW, Hajduk P, (1992) An immunohistochemical study of plasma albumin extravasation in the brain of mice after the administration of Clostridium perfringens type D epsilon toxin. Australian veterinary journal 69: 261-262.
35. Ghabriel MN, Zhu C, Reilly PL, Blumbergs PC, Manavis J, et al. (2000) Toxin-induced vasogenic cerebral oedema in a rat model. Acta neurochirurgica. Supplement 76: 231-236.
36. Zhu C, Ghabriel MN, Blumbergs PC, Reilly PL, Manavis J, et al. (2001) Clostridium perfringens prototoxin-induced alteration of endothelial barrier antigen (EBA) immunoreactivity at the blood-brain barrier (BBB). Experimental neurology 169: 72-82 doi: 10.1006/exnr.2001.7652.
37. Dawson J, (1916) The histology of multiple sclerosis. Trans R Soc Edinburgh 50: 517-578.
38. Erickson JE, Deibel RH, (1978) New medium for rapid screening and enumeration of Clostridium perfringens in foods. Applied and environmental microbiology 36: 567-571.
39. Meer RR, Songer JG, (1997) Multiplex polymerase chain reaction assay for genotyping Clostridium perfringens. American journal of veterinary research 58: 702-705.
40. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, et al. (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7: 615-625 doi: 10.1016/S1474-4422(08)70137-6.
41. Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, et al. (2003) Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Annals of neurology 53: 718-724 doi: 10.1002/ana.10551.
42. Horowitz AL, Kaplan RD, Grewe G, White RT, Salberg LM, (1989) The ovoid lesion: a new MR observation in patients with multiple sclerosis. AJNR Am J Neuroradiol 10: 303-305.
43. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology 69: 292-302 doi: 10.1002/ana.22366.
44. Havard HL, Hunter SE, Titball RW, (1992) Comparison of the nucleotide sequence and development of a PCR test for the epsilon toxin gene of Clostridium perfringens type B and type D. FEMS microbiology letters. 76: 77-81.
45. Carman RJ, Sayeed S, Li J, Genheimer CW, Hiltonsmith MF, Wilkins TD, (2008) Clostridium perfringens toxin genotypes in the feces of healthy North Americans. Anaerobe 14: 102-108.
46. Basilio D, Jennings-Antipov LD, Jakes KS, Finkelstein A, (2011) Trapping a translocating protein within the anthrax toxin channel: implications for the secondary structure of permeating proteins. The Journal of general physiology 137: 343-356 doi: 10.1085/jgp.201010578.
47. Christensen KA, Krantz BA, Melnyk RA, Collier RJ, (2005) Interaction of the 20 kDa and 63 kDa fragments of anthrax protective antigen: kinetics and thermodynamics. Biochemistry 44: 1047-1053 doi: 10.1021/bi047791s.
48. Collier RJ, Young JA, (2003) Anthrax toxin. Annual review of cell and developmental biology 19: 45-70 doi: 10.1146/annurev.cellbio.19.111301.140655.
49. Nablo BJ, Halverson KM, Robertson JW, Nguyen TL, Panchal RG, et al. (2008) Sizing the Bacillus anthracis PA63 channel with nonelectrolyte poly(ethylene glycols). Biophysical journal 95: 1157-1164 doi: 10.1529/biophysj.107.121715.
50. Alqurashi AM, (2013) Anthrax threat: a review of clinical and diagnostic measures. Journal of the Egyptian Society of Parasitology 43: 147-166.
51. Bossi P, Garin D, Guihot A, Gay F, Crance JM, et al. (2006) Bioterrorism: management of major biological agents. Cellular and molecular life sciences: CMLS 63: 2196-2212 doi: 10.1007/s00018-006-6308-z.
52. Doganay M, Metan G, Alp E, (2010) A review of cutaneous anthrax and its outcome. Journal of infection and public health 3: 98-105 doi: 10.1016/j.jiph.2010.07.004.
53. Blackwell TE, Butler DG, Bell JA, (1983) Enterotoxemia in the goat: the humoral response and local tissue reaction following vaccination with two different bacterin-toxoids. Can J Comp Med 47: 127-132.
54. Dorca-Arevalo J, Martin-Satue M, Blasi J, (2012) Characterization of the high affinity binding of epsilon toxin from Clostridium perfringens to the renal system. Veterinary microbiology 157: 179-189 doi: 10.1016/j.vetmic.2011.12.020.
55. Engell T, Krogsaa B, Lund-Andersen H, (1986) Breakdown of the blood-retinal barrier in multiple sclerosis measured by vitreous fluorophotometry. Acta ophthalmologica 64: 583-587.
56. Rucker CW, (1972) Sheathing of the retinal veins in multiple sclerosis. Review of pertinent literature. Mayo Clinic proceedings. Mayo Clinic 47: 335-340.
57. Gelfand JM, Cree BA, Nolan R, Arnow S, Green AJ, (2013) Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA neurology 70: 629-633 doi: 10.1001/jamaneurol.2013.1832.
58. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ, (2012) Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain: a journal of neurology 135: 1786-1793 doi: 10.1093/brain/aws098.
59. Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, et al. (2012) Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 11: 963-972 doi: 10.1016/S1474-4422(12)70213-2.
60. Schneider E, Zimmermann H, Oberwahrenbrock T, Kaufhold F, Kadas EM, et al. (2013) Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PloS one 8: e66151 doi: 10.1371/journal.pone.0066151.
61. Kurtzke JF, Gudmundsson KR, Bergmann S, (1982) Multiple sclerosis in Iceland: 1. Evidence of a postwar epidemic. Neurology 32: 143-150.
62. Kurtzke JF, Hyllested K, (1979) Multiple sclerosis in the Faroe Islands: I. Clinical and epidemiological features. Annals of neurology 5: 6-21 doi: 10.1002/ana.410050104.
63. Kurtzke JF, Hyllested K, (1986) Multiple sclerosis in the Faroe Islands. II. Clinical update, transmission, and the nature of MS. Neurology 36: 307-328.
64. Kurtzke JF, Hyllested K, Heltberg A, (1995) Multiple sclerosis in the Faroe Islands: transmission across four epidemics. Acta neurologica Scandinavica 91: 321-325.
65. Kurtzke JF, Heltberg A, (2001) Multiple sclerosis in the Faroe Islands: an epitome. Journal of clinical epidemiology 54: 1-22.
66. Kurtzke JF, Hyllested K, (1988) Validity of the epidemics of multiple sclerosis in the Faroe Islands. Neuroepidemiology 7: 190-227.
67. Kurtzke JF, (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6: 382-427.
68. Kundi M, (2007) Causality and the interpretation of epidemiologic evidence. Ciencia & saude coletiva 12: 419-428.
69. Morabia A, (1991) On the origin of Hill's causal criteria. Epidemiology 2: 367-369.
70. Vineis P, (1991) Causality assessment in epidemiology. Theoretical medicine 12: 171-181.
71. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of neurology 47: 707-717.
72. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H, (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain pathology 6: 259-274.
73. Itodo AE, Adesiyun AA, Adekeye JO, Umoh JU, (1986) Toxin-types of Clostridium perfringens strains isolated from sheep, cattle and paddock soils in Nigeria. Veterinary microbiology 12: 93-96.
74. Tamai E, Ishida T, Miyata S, Matsushita O, Suda H, et al. (2003) Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infection and immunity 71: 5371-5375.
75. Kerrison JB, Flynn T, Green WR, (1994) Retinal pathologic changes in multiple sclerosis. Retina 14: 445-451.